ArticleExploration (Beijing, China)2025
Specifically Breaking Through the Injured Blood-Brain Barrier With Tannic Acid-Based Nanomedicine for Ischemic Stroke Ischemia Reperfusion Treatment.
Article in Exploration (Beijing, China), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Dynamic Nanoscavengers With Boosted Antioxidative Properties for Hepatic Ischemia-Reperfusion Injury Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Heme cascade-triggered nanovesicles for myocardial ischemic core delivery.Bioactive materials · 2026Article
- Advances in Polydopamine-Based Nanoplatforms: Antioxidant Mechanisms and Applications in Oxidative Stress-Mediated Diseases.Nano-micro letters · 2026Review
- Targeting the oxidative microenvironment with a tannic acid-modified manganese dioxide nanozyme loaded with Honokiol nanoplatform to activate sirtuin 3-mediated deacetylation for alleviating cerebral ischemia-reperfusion injury.Journal of nanobiotechnology · 2026Article
- Plasma-Nanomedicine Synergistic Therapy for Brain Diseases: Current Status, Applications, and Challenges.Antioxidants (Basel, Switzerland) · 2026Review
- Review
- Bioinspired enzymatic polyphenolic nanoplatform for redox modulation and functional renal restoration in diabetic nephropathy.Regenerative biomaterials · 2026Article
- Exploring the molecular mechanism of dexmedetomidine in alleviating blood-brain barrier disruption in rats with cerebral ischemia reperfusion injury based on network pharmacology.Frontiers in molecular neuroscience · 2026Article
- YiQi-HuoXue prescription ameliorates LPS-induced sepsis-associated encephalopathy via VCAM-1-mediated microglial efferocytosis.Frontiers in immunology · 2026Article
- Nanotechnology-donated ischemic stroke therapeutics: evolving strategies from the basic to the cutting-edge.Theranostics · 2026Review
- A mitochondria-targeted nanomedicine for myocardial ischemia/reperfusion injury with synergistic antioxidant and anti-inflammatory properties.Journal of nanobiotechnology · 2025Article
- Specifically Breaking Through the Injured Blood-Brain Barrier With Tannic Acid-Based Nanomedicine for Ischemic Stroke Ischemia Reperfusion Treatment.Exploration (Beijing, China) · 2025Article
- Brain-Targeting siRNA Delivery to Tackle Alzheimer's Disease.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protecting neuronal mitochondria by eliminating the mitochondrial ROS (mtROS) storm is crucial to abrogate the neuronal damage cascade of ischemic stroke ischemia reperfusion (ISIR), which is a long-standing challenge in the field of ischemic stroke (IS). Existing blood-brain barrier (BBB) penetration methods are usually unable to distinguish between healthy brain tissue and cerebral infarction tissue, and BBB targeting is not compatible with mitochondrial targeting, resulting in a huge barrier to the specific elimination of mtROS in neuronal mitochondria in ISIR. This study introduces an elegantly designed tannic acid, polydopamine, and Mo-based heteropolyacid ternary composite nanomedicine (TPM), which not only has a superb ability to eliminate multiple ROS thanks to the introduction of polydopamine, but also can actively recognize the injured BBB site, specifically enter the neurons in the cerebral infarction area, and then highly specifically target the mitochondria of neurons to efficiently eliminate mtROS. TPM could significantly inhibit neuronal apoptosis by protecting mitochondria and eliminate inflammation by inhibiting activation of the STING pathway, thereby significantly reducing the size of cerebral infarction. This sequential targeting of TPM from the injured BBB to neuronal mitochondria provides a promising strategy to treat ISIR in the clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.